$CCCC News

Evercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12

C4 Therapeutics Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $6.152M Beat $3.333M Estimate

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Insight, Epidemiology, and Market Forecast Report 2022-2026 & 2026-2036 Featuring Novartis, Genentech, Fore Biotherapeutic, and C4 Therapeutics

Roche and C4 Therapeutics to advance degrader-antibody conjugates research

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics shares are trading higher after the company announced that it has entered into a new collaboration agreement with Roche to advance research in the emerging degrader-antibody conjugate modality.

C4 Therapeutics shares are trading higher after the company announced that it has entered into a new collaboration agreement with Roche to advance research in the emerging degrader-antibody conjugate modality.

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Starts Trial For New Multiple Myeloma Drug Combo

Analysts See Significant Upside in C4 Therapeutics (CCCC) Stock

C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact

C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

C4 Therapeutics, Inc. (CCCC) Presents at TD Cowen 46th Annual Health Care Conference - Slideshow

Is BrightSpring Health Services, Inc. (BTSG) Stock Outpacing Its Medical Peers This Year?

Barclays Maintains Overweight on C4 Therapeutics, Raises Price Target to $7

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Earnings Summary: C4 Therapeutics Q4